美敦力公司Medtronic（MDT）2026财年第三季度业绩报告「NYSE」（英文版）（6页）.pdf

1、 NEWS RELEASE FOR IMMEDIATE RELEASE Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters Cardiovascular portfolio up 11%year-over-year;Cardiac Ablation Solutions grew 80%on strength of pulsed field ablation portfolio GALWAY,Ireland February

2、 17,2026 Medtronic plc(NYSE:MDT),a global leader in healthcare technology,today announced financial results for its third quarter(Q3)of fiscal year 2026(FY26),which ended January 23,2026.Q3 Key Highlights Revenue of$9.0 billion,increased 8.7%as reported and 6.0%organic,50 basis points ahead of Q3 gu

3、idance GAAP diluted EPS of$0.89;non-GAAP diluted EPS of$1.36,three cents ahead of Q3 guidance mid-point Company reiterates FY26 organic revenue growth and EPS guidance Cardiac Ablation Solutions revenue increased 80%,including 137%in the U.S.,on strength of pulsed field ablation(PFA)portfolio Secure

4、d CE Mark for Sphere-360 and initiated U.S.pivotal trial Secured U.S.FDA clearance for Hugo robotic-assisted surgery;first cases completed this month Diabetes revenue increased 8.3%led by double-digit strength in International markets Executing M&A strategy with two key transactions in the quarter:C

5、athWorks in Coronary and Renal Denervation and Anteris in Structural Heart “Q3 marks another strong quarter,delivering 6%organic revenue growth,ahead of guidance,demonstrating the strength of our portfolio,”said Geoff Martha,Medtronic chairman and chief executive officer.“By unlocking new markets an

6、d investing in high-growth opportunities,we are accelerating performance across the company.Our innovation pipeline and portfolio breadth give us confidence in our ability to sustain long-term growth.Its an exciting time for Medtronic.”Financial Results Medtronic reported Q3 worldwide revenue of$9.0